These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12206749)

  • 61. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis.
    Barger RL; Nandalur KR
    Acad Radiol; 2012 Feb; 19(2):153-8. PubMed ID: 22104289
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness of PET imaging in clinical oncology.
    Valk PE; Pounds TR; Tesar RD; Hopkins DM; Haseman MK
    Nucl Med Biol; 1996 Aug; 23(6):737-43. PubMed ID: 8940715
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolic imaging by positron emission tomography in oncology.
    Leskinen S; Lapela M; Lindholm P; Minn H
    Ann Med; 1997 Aug; 29(4):271-4. PubMed ID: 9375982
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Positron emission-computed tomography in diagnosis and staging of lung neoplasms. Personal experience].
    Mezzetti M; Calati AM; Schubert L
    Minerva Chir; 2002 Aug; 57(4):461-5. PubMed ID: 12145576
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recommendations on the use of 18F-FDG PET in oncology.
    Fletcher JW; Djulbegovic B; Soares HP; Siegel BA; Lowe VJ; Lyman GH; Coleman RE; Wahl R; Paschold JC; Avril N; Einhorn LH; Suh WW; Samson D; Delbeke D; Gorman M; Shields AF
    J Nucl Med; 2008 Mar; 49(3):480-508. PubMed ID: 18287273
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management.
    Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP
    Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.
    Christensen JA; Nathan MA; Mullan BP; Hartman TE; Swensen SJ; Lowe VJ
    AJR Am J Roentgenol; 2006 Nov; 187(5):1361-7. PubMed ID: 17056930
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Positron emission tomography in the Netherlands: need to expand the capacity].
    Comans EF; Smit EF
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1817-9. PubMed ID: 12382364
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
    Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
    J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner.
    Hicks RJ; Binns DS; Fawcett ME; Ware RE; Kalff V; McKenzie AF; Zalcberg JP; Peters LJ
    Med J Aust; 1999 Nov; 171(10):529-32. PubMed ID: 10816703
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan.
    Dewan NA; Shehan CJ; Reeb SD; Gobar LS; Scott WJ; Ryschon K
    Chest; 1997 Aug; 112(2):416-22. PubMed ID: 9266877
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of clinical utility of 18F-FDG PET in patients with head and neck cancer: a probability analysis.
    Goerres GW; Mosna-Firlejczyk K; Steurer J; von Schulthess GK; Bachmann LM
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):562-71. PubMed ID: 12589477
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Positron emission tomography (PET) in clinical oncology [Part III]].
    Cabrera Villegas A; García Velloso MJ; Gámez Cenzano C
    Rev Esp Med Nucl; 2002 Jul; 21(4):304-20; quiz 321-3. PubMed ID: 12206748
    [No Abstract]   [Full Text] [Related]  

  • 74. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
    Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
    Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Positron Emission Tomography-Computed Tomography for Patients with Recurrent Colorectal Liver Metastases: Impact on Restaging and Treatment Planning.
    Viganò L; Lopci E; Costa G; Rodari M; Poretti D; Pedicini V; Solbiati L; Chiti A; Torzilli G
    Ann Surg Oncol; 2017 Apr; 24(4):1029-1036. PubMed ID: 27807727
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images.
    Hübner KF; Buonocore E; Gould HR; Thie J; Smith GT; Stephens S; Dickey J
    Clin Nucl Med; 1996 Dec; 21(12):941-9. PubMed ID: 8957608
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Relevance of positron emission tomography (PET) in oncology.
    Weber WA; Avril N; Schwaiger M
    Strahlenther Onkol; 1999 Aug; 175(8):356-73. PubMed ID: 10481766
    [TBL] [Abstract][Full Text] [Related]  

  • 78. How to scan who: the delicate balance between selecting the patient and selecting the imaging protocol.
    Hustinx R
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):5-7. PubMed ID: 27624189
    [No Abstract]   [Full Text] [Related]  

  • 79. FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review.
    Groheux D; Quere G; Blanc E; Lemarignier C; Vercellino L; de Margerie-Mellon C; Merlet P; Querellou S
    Diagn Interv Imaging; 2016 Oct; 97(10):1003-1017. PubMed ID: 27567555
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Positron emission tomography using 18-FDG-PET in radiologically indeterminate pulmonary lesions].
    Ruiz-Hernández G; de Juan R; Samanes A; Verea H; Peñas JM; Veres A; Lapeña L; Montz R; Carreras JL
    An Med Interna; 2004 Jan; 21(1):12-6. PubMed ID: 15195479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.